Initiate the management, oversight, and conduct of the niaid dmid clinical trial titled "a multicenter, adaptive, randomized blinded controlled trial of the safety and efficacy of investigational…
Ended Awarded Last action
- Contract number
- 75N91020F00010
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $72,440,795
Award facts
- Contract value 100% obligated
- $72,440,795.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | -$11,000,000 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $25,075,500 | |
| Supplemental Agreement for work within scope | $18,166,213 | |
| Definitize Letter Contract | $23,414,109 | |
| Supplemental Agreement for work within scope | $10,104,139 | |
| Original award | $6,680,834 |
About this award
Leidos Biomedical Research Inc. was awarded a $72.4 million cost-plus-fixed-fee delivery order by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to manage, oversee, and conduct a multi-center clinical trial titled "A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19." The prime contractor will perform work at Fort Detrick, Maryland from April 2020 through December 2023. A subcontract valued at an undisclosed amount was issued to the Board of Regents of the University of Nebraska Medical Center to provide institutional review board services for multiple sites participating in the National Ebola Training and Education Center clinical trial.
Description
Initiate the management, oversight, and conduct of the niaid dmid clinical trial titled "a multicenter, adaptive, randomized blinded controlled trial of the safety and efficacy of investigational therapeutics for the treatment of covid-19".
Quick answers
Who was awarded contract 75N91020F00010?
75N91020F00010 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on April 1, 2020.
How much is contract 75N91020F00010 worth?
The government has obligated $72,440,795 on 75N91020F00010.
Which agency awarded contract 75N91020F00010?
National Cancer Institute (National Institutes of Health) awarded 75N91020F00010, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91020F00010 an order under another contract?
Yes. 75N91020F00010 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91020F00010 competed?
The extent of competition for 75N91020F00010 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award